{"entity":{"id":"nct07720193","kind":"trial","name":"A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC","aka":[],"tldr":"A phase 3 trial of Opamtistomig run by Nanjing Leads Biolabs Co.,Ltd, not yet recruiting.","summary":"A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC is a phase 3 interventional study registered as NCT07720193 by Nanjing Leads Biolabs Co.,Ltd, with 280 participants planned, started 2026-11-16. Conditions recorded: Advanced Extrapulmonary Neuroendocrine Carcinoma. Interventions recorded: LBL-024 for Injection, Etoposide injection, Cisplatin injection, Carboplatin injection and LBL-024 placebo for injection.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07720193","url":"https://clinicaltrials.gov/study/NCT07720193"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":["opamtistomig"],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07720193","phase":"3","setting":"A Randomized, Double-blind, Placebo-controlled, Phase III Trial of LBL-024 Combined With Platinum-based Chemotherapy as First-line Treatment of Patients With Advanced Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)","sponsor":"Nanjing Leads Biolabs Co.,Ltd","enrolled":280,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07720193/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"drug":[{"id":"opamtistomig","kind":"drug","name":"Opamtistomig","route":"/drugs/opamtistomig/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}]}}